Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 261

1.

EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.

Wassef M, Luscan A, Aflaki S, Zielinski D, Jansen PWTC, Baymaz HI, Battistella A, Kersouani C, Servant N, Wallace MR, Romero P, Kosmider O, Just PA, Hivelin M, Jacques S, Vincent-Salomon A, Vermeulen M, Vidaud M, Pasmant E, Margueron R.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6075-6080. doi: 10.1073/pnas.1814634116. Epub 2019 Mar 13.

PMID:
30867289
2.

A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.

Coussy F, de Koning L, Lavigne M, Bernard V, Ouine B, Boulai A, El Botty R, Dahmani A, Montaudon E, Assayag F, Morisset L, Huguet L, Sourd L, Painsec P, Callens C, Chateau-Joubert S, Servely JL, Larcher T, Reyes C, Girard E, Pierron G, Laurent C, Vacher S, Baulande S, Melaabi S, Vincent-Salomon A, Gentien D, Dieras V, Bieche I, Marangoni E.

Int J Cancer. 2019 Mar 12. doi: 10.1002/ijc.32266. [Epub ahead of print]

PMID:
30859564
3.

ESR1 mutations in metastatic lobular breast cancer patients.

Desmedt C, Pingitore J, Rothé F, Marchio C, Clatot F, Rouas G, Richard F, Bertucci F, Mariani O, Galant C, Fribbens C, O'Leary B, van den Eynden G, Salgado R, Turner NC, Piccart M, Vincent-Salomon A, Pruneri G, Larsimont D, Sotiriou C.

NPJ Breast Cancer. 2019 Feb 22;5:9. doi: 10.1038/s41523-019-0104-z. eCollection 2019.

4.

The circular RNome of primary breast cancer.

Smid M, Wilting SM, Uhr K, Rodríguez-González FG, de Weerd V, Prager-Van der Smissen WJC, van der Vlugt-Daane M, van Galen A, Nik-Zainal S, Butler A, Martin S, Davies HR, Staaf J, van de Vijver MJ, Richardson AL, MacGrogan G, Salgado R, van den Eynden GGGM, Purdie CA, Thompson AM, Caldas C, Span PN, Sweep FCGJ, Simpson PT, Lakhani SR, Van Laere S, Desmedt C, Paradiso A, Eyfjord J, Broeks A, Vincent-Salomon A, Futreal AP, Knappskog S, King T, Viari A, Børresen-Dale AL, Stunnenberg HG, Stratton M, Foekens JA, Sieuwerts AM, Martens JWM.

Genome Res. 2019 Mar;29(3):356-366. doi: 10.1101/gr.238121.118. Epub 2019 Jan 28.

PMID:
30692147
5.

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, Van't Veer L, Tutt A, Knappskog S, Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2019 Feb;566(7742):E1. doi: 10.1038/s41586-019-0883-2.

PMID:
30659290
6.

The Genomic Landscape of Mucinous Breast Cancer.

Pareja F, Lee JY, Brown DN, Piscuoglio S, Gularte-Mérida R, Selenica P, Da Cruz Paula A, Arunachalam S, Kumar R, Geyer FC, Silveira C, da Silva EM, Li A, Marchiò C, Ng CKY, Mariani O, Fuhrmann L, Wen HY, Norton L, Vincent-Salomon A, Brogi E, Reis-Filho JS, Weigelt B.

J Natl Cancer Inst. 2019 Jan 11. doi: 10.1093/jnci/djy216. [Epub ahead of print]

PMID:
30649385
7.

Radiation therapy after sentinel lymph node biopsy for early stage breast cancer using a magnetic tracer: Results of a single institutional prospective study of tolerance.

Bazire L, Alran S, El Bamrani S, Gaujal L, Vincent-Salomon A, Tardivon A, Kirova YM.

Cancer Radiother. 2019 Feb;23(1):23-27. doi: 10.1016/j.canrad.2018.03.008. Epub 2018 Dec 12.

PMID:
30553652
8.

Clinical Validity of HPV Circulating Tumor DNA in Advanced Anal Carcinoma: An Ancillary Study to the Epitopes-HPV02 Trial.

Bernard-Tessier A, Jeannot E, Guenat D, Debernardi A, Michel M, Proudhon C, Vincent-Salomon A, Bièche I, Pierga JY, Buecher B, Meurisse A, François É, Cohen R, Jary M, Vendrely V, Samalin E, El Hajbi F, Baba-Hamed N, Borg C, Bidard FC, Kim S.

Clin Cancer Res. 2019 Apr 1;25(7):2109-2115. doi: 10.1158/1078-0432.CCR-18-2984. Epub 2018 Nov 30.

PMID:
30504426
9.

Distinct expression profiles and functions of Kindlins in breast cancer.

Azorin P, Bonin F, Moukachar A, Ponceau A, Vacher S, Bièche I, Marangoni E, Fuhrmann L, Vincent-Salomon A, Lidereau R, Driouch K.

J Exp Clin Cancer Res. 2018 Nov 26;37(1):281. doi: 10.1186/s13046-018-0955-4.

10.

Combinatorial expression of microtubule-associated EB1 and ATIP3 biomarkers improves breast cancer prognosis.

Rodrigues-Ferreira S, Nehlig A, Monchecourt C, Nasr S, Fuhrmann L, Lacroix-Triki M, Garberis I, Scott V, Delaloge S, Pistilli B, Vielh P, Dubois T, Vincent-Salomon A, André F, Nahmias C.

Breast Cancer Res Treat. 2019 Feb;173(3):573-583. doi: 10.1007/s10549-018-5026-1. Epub 2018 Oct 27.

PMID:
30368744
11.

RalB directly triggers invasion downstream Ras by mobilizing the Wave complex.

Zago G, Veith I, Singh MK, Fuhrmann L, De Beco S, Remorino A, Takaoka S, Palmeri M, Berger F, Brandon N, El Marjou A, Vincent-Salomon A, Camonis J, Coppey M, Parrini MC.

Elife. 2018 Oct 15;7. pii: e40474. doi: 10.7554/eLife.40474.

12.

Malignant Transformation of a Multi-Operated Divided Nevus of the Eyelids.

Lemaître S, Gardrat S, Vincent-Salomon A, Galatoire O, Lévy-Gabriel C, Desjardins L.

Ocul Oncol Pathol. 2018 Sep;4(2):112-115. doi: 10.1159/000479069. Epub 2017 Sep 2.

13.

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.

Cottu P, D'Hondt V, Dureau S, Lerebours F, Desmoulins I, Heudel PE, Duhoux FP, Levy C, Mouret-Reynier MA, Dalenc F, Frenel JS, Jouannaud C, Venat-Bouvet L, Nguyen S, Ferrero JM, Canon JL, Grenier J, Callens C, Gentien D, Lemonnier J, Vincent-Salomon A, Delaloge S.

Ann Oncol. 2018 Dec 1;29(12):2334-2340. doi: 10.1093/annonc/mdy448.

PMID:
30307466
14.

Disseminated Tumor Cells Predict Efficacy of Regional Nodal Irradiation in Early Stage Breast Cancer.

Mignot F, Loirat D, Dureau S, Bataillon G, Caly M, Vincent-Salomon A, Berger F, Fourquet A, Pierga JY, Kirova YM, Bidard FC.

Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):389-396. doi: 10.1016/j.ijrobp.2018.09.033. Epub 2018 Oct 4.

PMID:
30291993
15.

VOPP1 promotes breast tumorigenesis by interacting with the tumor suppressor WWOX.

Bonin F, Taouis K, Azorin P, Petitalot A, Tariq Z, Nola S, Bouteille N, Tury S, Vacher S, Bièche I, Rais KA, Pierron G, Fuhrmann L, Vincent-Salomon A, Formstecher E, Camonis J, Lidereau R, Lallemand F, Driouch K.

BMC Biol. 2018 Oct 2;16(1):109. doi: 10.1186/s12915-018-0576-6.

16.

A New Transcutaneous Method for Breast Cancer Detection with Dogs.

Thuleau A, Gilbert C, Bauër P, Alran S, Fourchotte V, Guillot E, Vincent-Salomon A, Kerihuel JC, Dugay J, Semetey V, Kriegel I, Fromantin I.

Oncology. 2019;96(2):110-113. doi: 10.1159/000492895. Epub 2018 Oct 2.

PMID:
30278460
17.

PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers.

Gentric G, Kieffer Y, Mieulet V, Goundiam O, Bonneau C, Nemati F, Hurbain I, Raposo G, Popova T, Stern MH, Lallemand-Breitenbach V, Müller S, Cañeque T, Rodriguez R, Vincent-Salomon A, de Thé H, Rossignol R, Mechta-Grigoriou F.

Cell Metab. 2019 Jan 8;29(1):156-173.e10. doi: 10.1016/j.cmet.2018.09.002. Epub 2018 Sep 20.

18.

Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression.

Romero P, Benhamo V, Deniziaut G, Fuhrmann L, Berger F, Manié E, Bhalshankar J, Vacher S, Laurent C, Marangoni E, Gruel N, MacGrogan G, Rouzier R, Delattre O, Popova T, Reyal F, Stern MH, Stoppa-Lyonnet D, Marchiò C, Bièche I, Vincent-Salomon A.

Am J Pathol. 2018 Oct;188(10):2378-2391. doi: 10.1016/j.ajpath.2018.06.021. Epub 2018 Aug 1.

PMID:
30075151
19.

Coronin 1C promotes triple-negative breast cancer invasiveness through regulation of MT1-MMP traffic and invadopodia function.

Castagnino A, Castro-Castro A, Irondelle M, Guichard A, Lodillinsky C, Fuhrmann L, Vacher S, Agüera-González S, Zagryazhskaya-Masson A, Romao M, El Kesrouani C, Noegel AA, Dubois T, Raposo G, Bear JE, Clemen CS, Vincent-Salomon A, Bièche I, Chavrier P.

Oncogene. 2018 Dec;37(50):6425-6441. doi: 10.1038/s41388-018-0422-x. Epub 2018 Jul 31.

PMID:
30065298
20.

Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma.

Cabel L, Jeannot E, Bieche I, Vacher S, Callens C, Bazire L, Morel A, Bernard-Tessier A, Chemlali W, Schnitzler A, Lièvre A, Otz J, Minsat M, Vincent-Salomon A, Pierga JY, Buecher B, Mariani P, Proudhon C, Bidard FC, Cacheux W.

Clin Cancer Res. 2018 Nov 15;24(22):5767-5771. doi: 10.1158/1078-0432.CCR-18-0922. Epub 2018 Jul 27.

PMID:
30054279
21.

Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific.

Michea P, Noël F, Zakine E, Czerwinska U, Sirven P, Abouzid O, Goudot C, Scholer-Dahirel A, Vincent-Salomon A, Reyal F, Amigorena S, Guillot-Delost M, Segura E, Soumelis V.

Nat Immunol. 2018 Aug;19(8):885-897. doi: 10.1038/s41590-018-0145-8. Epub 2018 Jul 16.

PMID:
30013147
22.

The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.

Marchiò C, Dell'Orto P, Annaratone L, Geyer FC, Venesio T, Berrino E, Verdun di Cantogno L, Garofoli A, Rangel N, Casorzo L, dell'Aglio C, Gugliotta P, Trisolini E, Beano A, Pietribiasi F, Orlassino R, Cassoni P, Pich A, Montemurro F, Mottolese M, Vincent-Salomon A, Penault-Llorca F, Medico E, Ng CKY, Viale G, Sapino A.

Am J Surg Pathol. 2018 Sep;42(9):1190-1200. doi: 10.1097/PAS.0000000000001100.

23.

Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.

Renault AL, Mebirouk N, Fuhrmann L, Bataillon G, Cavaciuti E, Le Gal D, Girard E, Popova T, La Rosa P, Beauvallet J, Eon-Marchais S, Dondon MG, d'Enghien CD, Laugé A, Chemlali W, Raynal V, Labbé M, Bièche I, Baulande S, Bay JO, Berthet P, Caron O, Buecher B, Faivre L, Fresnay M, Gauthier-Villars M, Gesta P, Janin N, Lejeune S, Maugard C, Moutton S, Venat-Bouvet L, Zattara H, Fricker JP, Gladieff L, Coupier I; CoF-AT; GENESIS; kConFab, Chenevix-Trench G, Hall J, Vincent-Salomon A, Stoppa-Lyonnet D, Andrieu N, Lesueur F.

Breast Cancer Res. 2018 Apr 17;20(1):28. doi: 10.1186/s13058-018-0951-9.

24.

Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.

Basse C, Morel C, Alt M, Sablin MP, Franck C, Pierron G, Callens C, Melaabi S, Masliah-Planchon J, Bataillon G, Gardrat S, Lavigne M, Bonsang B, Vaflard P, Pons Tostivint E, Dubot C, Loirat D, Marous M, Geiss R, Clément N, Schleiermacher G, Kamoun C, Girard E, Ardin M, Benoist C, Bernard V, Mariani O, Rouzier R, Tresca P, Servois V, Vincent-Salomon A, Bieche I, Le Tourneau C, Kamal M.

ESMO Open. 2018 Apr 6;3(3):e000339. doi: 10.1136/esmoopen-2018-000339. eCollection 2018.

25.

High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast.

Bataillon G, Fuhrmann L, Girard E, Menet E, Laé M, Capovilla M, Treilleux I, Arnould L, Penault-Llorca F, Rouzier R, Marchiò C, Bieche I, Vincent-Salomon A.

Histopathology. 2018 Aug;73(2):273-283. doi: 10.1111/his.13514. Epub 2018 May 7.

26.

miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers.

Givel AM, Kieffer Y, Scholer-Dahirel A, Sirven P, Cardon M, Pelon F, Magagna I, Gentric G, Costa A, Bonneau C, Mieulet V, Vincent-Salomon A, Mechta-Grigoriou F.

Nat Commun. 2018 Mar 13;9(1):1056. doi: 10.1038/s41467-018-03348-z.

27.

Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.

Marangoni E, Laurent C, Coussy F, El-Botty R, Château-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Nemati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noel A, Vincent-Salomon A, Lae M, Decaudin D, Roman-Roman S, Bièche I, Piccart M, Reyal F.

Clin Cancer Res. 2018 Jun 1;24(11):2605-2615. doi: 10.1158/1078-0432.CCR-17-3490. Epub 2018 Feb 20.

28.

Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer.

Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, Sirven P, Magagna I, Fuhrmann L, Bernard C, Bonneau C, Kondratova M, Kuperstein I, Zinovyev A, Givel AM, Parrini MC, Soumelis V, Vincent-Salomon A, Mechta-Grigoriou F.

Cancer Cell. 2018 Mar 12;33(3):463-479.e10. doi: 10.1016/j.ccell.2018.01.011. Epub 2018 Feb 15.

29.

PET/CT imaging in management of concomitant Hodgkin lymphoma and tuberculosis - a problem solver tool.

Jehanno N, Cassou-Mounat T, Vincent-Salomon A, Luporsi M, Bedoui M, Kuhnowski F.

Clin Case Rep. 2017 Nov 29;6(1):232-234. doi: 10.1002/ccr3.1248. eCollection 2018 Jan.

30.

Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma.

Hamy AS, Lam GT, Laas E, Darrigues L, Balezeau T, Guerin J, Livartowski A, Sadacca B, Pierga JY, Vincent-Salomon A, Coussy F, Becette V, Bonsang-Kitzis H, Rouzier R, Feron JG, Benchimol G, Laé M, Reyal F.

Breast Cancer Res Treat. 2018 Jun;169(2):295-304. doi: 10.1007/s10549-017-4610-0. Epub 2018 Jan 27.

PMID:
29374852
31.

Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast.

Piscuoglio S, Ng CKY, Geyer FC, Burke KA, Cowell CF, Martelotto LG, Natrajan R, Popova T, Maher CA, Lim RS, Bruijn I, Mariani O, Norton L, Vincent-Salomon A, Weigelt B, Reis-Filho JS.

NPJ Breast Cancer. 2017 Dec 1;3:48. doi: 10.1038/s41523-017-0048-0. eCollection 2017.

32.

Invasion in breast lesions: the role of the epithelial-stroma barrier.

Rakha EA, Miligy IM, Gorringe KL, Toss MS, Green AR, Fox SB, Schmitt FC, Tan PH, Tse GM, Badve S, Decker T, Vincent-Salomon A, Dabbs DJ, Foschini MP, Moreno F, Wentao Y, Geyer FC, Reis-Filho JS, Pinder SE, Lakhani SR, Ellis IO.

Histopathology. 2018 Jun;72(7):1075-1083. doi: 10.1111/his.13446. Epub 2018 Feb 13. Review.

PMID:
29197112
33.

MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene.

Kim J, Geyer FC, Martelotto LG, Ng CK, Lim RS, Selenica P, Li A, Pareja F, Fusco N, Edelweiss M, Kumar R, Gularte-Merida R, Forbes AN, Khurana E, Mariani O, Badve S, Vincent-Salomon A, Norton L, Reis-Filho JS, Weigelt B.

J Pathol. 2018 Feb;244(2):143-150. doi: 10.1002/path.5006. Epub 2017 Dec 28.

34.

Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR.

Decraene C, Silveira AB, Bidard FC, Vallée A, Michel M, Melaabi S, Vincent-Salomon A, Saliou A, Houy A, Milder M, Lantz O, Ychou M, Denis MG, Pierga JY, Stern MH, Proudhon C.

Clin Chem. 2018 Feb;64(2):317-328. doi: 10.1373/clinchem.2017.272518. Epub 2017 Nov 9.

35.

Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer.

Hamy AS, Pierga JY, Sabaila A, Laas E, Bonsang-Kitzis H, Laurent C, Vincent-Salomon A, Cottu P, Lerebours F, Rouzier R, Lae M, Reyal F.

Ann Oncol. 2017 Sep 1;28(9):2233-2240. doi: 10.1093/annonc/mdx309.

PMID:
28911063
36.

Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.

Lavigne M, Menet E, Tille JC, Lae M, Fuhrmann L, Bonneau C, Deniziaut G, Melaabi S, Ng CCK, Marchiò C, Rouzier R, Bièche I, Vincent-Salomon A.

Mod Pathol. 2018 Jan;31(1):68-82. doi: 10.1038/modpathol.2017.107. Epub 2017 Sep 8.

37.

[Internal quality control on HER2 status determination in breast cancers: Experience of a cancer center].

Ngo C, Laé M, Ratour J, Hamel F, Taris C, Caly M, Le Cunff A, Reyal F, Kirova Y, Pierga JY, Vincent-Salomon A.

Bull Cancer. 2017 Jul - Aug;104(7-8):608-617. doi: 10.1016/j.bulcan.2017.05.002. Epub 2017 Jun 7. French.

PMID:
28595742
38.

Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.

Ng CKY, Bidard FC, Piscuoglio S, Geyer FC, Lim RS, de Bruijn I, Shen R, Pareja F, Berman SH, Wang L, Pierga JY, Vincent-Salomon A, Viale A, Norton L, Sigal B, Weigelt B, Cottu P, Reis-Filho JS.

Clin Cancer Res. 2017 Aug 1;23(15):4402-4415. doi: 10.1158/1078-0432.CCR-16-3115. Epub 2017 Mar 28.

39.

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.

Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S.

Nat Med. 2017 Apr;23(4):517-525. doi: 10.1038/nm.4292. Epub 2017 Mar 13.

40.

Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers.

Bonsang-Kitzis H, Mouttet-Boizat D, Guillot E, Feron JG, Fourchotte V, Alran S, Pierga JY, Cottu P, Lerebours F, Stevens D, Vincent-Salomon A, Sigal-Zafrani B, Campana F, Rouzier R, Reyal F.

PLoS One. 2017 Feb 27;12(2):e0169962. doi: 10.1371/journal.pone.0169962. eCollection 2017.

41.

Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers.

Thomas C, Henry W, Cuiffo BG, Collmann AY, Marangoni E, Benhamo V, Bhasin MK, Fan C, Fuhrmann L, Baldwin AS, Perou C, Vincent-Salomon A, Toker A, Karnoub AE.

Sci Signal. 2017 Feb 21;10(467). pii: eaah4674. doi: 10.1126/scisignal.aah4674.

42.

The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.

Ng CKY, Piscuoglio S, Geyer FC, Burke KA, Pareja F, Eberle CA, Lim RS, Natrajan R, Riaz N, Mariani O, Norton L, Vincent-Salomon A, Wen YH, Weigelt B, Reis-Filho JS.

Clin Cancer Res. 2017 Jul 15;23(14):3859-3870. doi: 10.1158/1078-0432.CCR-16-2857. Epub 2017 Feb 2.

43.

Evisceration and ocular tumors: What are the consequences?

Lemaître S, Lecler A, Lévy-Gabriel C, Reyes C, Desjardins L, Gentien D, Zmuda M, Jacomet PV, Lumbroso-Le Rouic L, Dendale R, Vincent-Salomon A, Pierron G, Galatoire O, Cassoux N.

J Fr Ophtalmol. 2017 Feb;40(2):93-101. doi: 10.1016/j.jfo.2016.10.007. Epub 2017 Jan 23.

44.

A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers.

Ferrari A, Sertier AS, Vincent-Salomon A, Pivot X, Pauporté I, Saintigny P, Birnbaum D, Viari A.

Mol Cell Oncol. 2016 Sep 12;3(6):e1232186. doi: 10.1080/23723556.2016.1232186. eCollection 2016.

45.

Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.

Riva F, Bidard FC, Houy A, Saliou A, Madic J, Rampanou A, Hego C, Milder M, Cottu P, Sablin MP, Vincent-Salomon A, Lantz O, Stern MH, Proudhon C, Pierga JY.

Clin Chem. 2017 Mar;63(3):691-699. doi: 10.1373/clinchem.2016.262337. Epub 2017 Jan 10.

46.

Tumoral heterogeneity of breast cancer.

Roulot A, Héquet D, Guinebretière JM, Vincent-Salomon A, Lerebours F, Dubot C, Rouzier R.

Ann Biol Clin (Paris). 2016 Dec 1;74(6):653-660. Review.

PMID:
27848916
47.

Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.

Fusco N, Geyer FC, De Filippo MR, Martelotto LG, Ng CK, Piscuoglio S, Guerini-Rocco E, Schultheis AM, Fuhrmann L, Wang L, Jungbluth AA, Burke KA, Lim RS, Vincent-Salomon A, Bamba M, Moritani S, Badve SS, Ichihara S, Ellis IO, Reis-Filho JS, Weigelt B.

Mod Pathol. 2016 Nov;29(11):1292-1305. doi: 10.1038/modpathol.2016.134. Epub 2016 Aug 5.

48.

Choroidal melanoma and pregnancy.

Lemaître S, Lévy-Gabriel C, Desjardins L, Plancher C, Asselain B, Vincent-Salomon A, Lumbroso-Le Rouic L, Dendale R, Rouzier R, Delacroix S, Cassoux N.

Acta Ophthalmol. 2016 Nov;94(7):e652-e660. doi: 10.1111/aos.12984. Epub 2016 Mar 24.

49.

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.

Lefort S, Thuleau A, Kieffer Y, Sirven P, Bieche I, Marangoni E, Vincent-Salomon A, Mechta-Grigoriou F.

Oncogene. 2017 Mar 2;36(9):1211-1222. doi: 10.1038/onc.2016.284. Epub 2016 Sep 26.

50.

Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.

Smid M, Rodríguez-González FG, Sieuwerts AM, Salgado R, Prager-Van der Smissen WJ, Vlugt-Daane MV, van Galen A, Nik-Zainal S, Staaf J, Brinkman AB, van de Vijver MJ, Richardson AL, Fatima A, Berentsen K, Butler A, Martin S, Davies HR, Debets R, Gelder ME, van Deurzen CH, MacGrogan G, Van den Eynden GG, Purdie C, Thompson AM, Caldas C, Span PN, Simpson PT, Lakhani SR, Van Laere S, Desmedt C, Ringnér M, Tommasi S, Eyford J, Broeks A, Vincent-Salomon A, Futreal PA, Knappskog S, King T, Thomas G, Viari A, Langerød A, Børresen-Dale AL, Birney E, Stunnenberg HG, Stratton M, Foekens JA, Martens JW.

Nat Commun. 2016 Sep 26;7:12910. doi: 10.1038/ncomms12910.

Supplemental Content

Loading ...
Support Center